Cargando…

Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows

About one-fourth of adults globally suffer from nonalcoholic fatty liver disease (NAFLD), which is becoming a leading cause of chronic liver disease worldwide. Its prevalence has rapidly increased in recent years, and is projected to increase even more. NAFLD is a leading cause of hepatocellular car...

Descripción completa

Detalles Bibliográficos
Autores principales:	Costante, Federico, Airola, Carlo, Santopaolo, Francesco, Gasbarrini, Antonio, Pompili, Maurizio, Ponziani, Francesca Romana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516656/ https://www.ncbi.nlm.nih.gov/pubmed/36187401 http://dx.doi.org/10.4251/wjgo.v14.i9.1622

Ejemplares similares

Molecular and Clinical Features of Hepatocellular Carcinoma in Patients with HBV-HDV Infection
por: Costante, Federico, et al.
Publicado: (2023)

Gut Microbiota and Infectious Complications in Advanced Chronic Liver Disease: Focus on Spontaneous Bacterial Peritonitis
por: Maccauro, Valeria, et al.
Publicado: (2023)

Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies
por: Maestri, Marta, et al.
Publicado: (2023)

Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives
por: Pallozzi, Maria, et al.
Publicado: (2022)

Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment
por: Stella, Leonardo, et al.
Publicado: (2022)

Bariatric Surgery and Liver Disease: General Considerations and Role of the Gut–Liver Axis
por: Cerreto, Maria, et al.
Publicado: (2021)

Microvascular Thrombosis and Liver Fibrosis Progression: Mechanisms and Clinical Applications
por: Airola, Carlo, et al.
Publicado: (2023)

Fecal Microbiota Transplantation in Patients with HBV Infection or Other Chronic Liver Diseases: Update on Current Knowledge and Future Perspectives
por: Paratore, Mattia, et al.
Publicado: (2021)

Correlation Between Liver Function Tests Abnormalities and Interleukin-6 Serum Levels in Patients With SARS-CoV-2 Infection
por: Ponziani, Francesca Romana, et al.
Publicado: (2021)

Type 2 Diabetes Mellitus and Liver Disease: Across the Gut–Liver Axis from Fibrosis to Cancer
por: Manilla, Vittoria, et al.
Publicado: (2023)

Risk factors for portal vein thrombosis or venous thromboembolism in a large cohort of hospitalized cirrhotic patients
por: Faccia, Mariella, et al.
Publicado: (2022)

Gut Microbiota and Neuroinflammation in Acute Liver Failure and Chronic Liver Disease
por: Giuli, Lucia, et al.
Publicado: (2023)

Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma
por: Ponziani, Francesca Romana, et al.
Publicado: (2019)

Low seroprevalence of SARS-CoV-2 antibodies in cirrhotic patients
por: Del Zompo, Fabio, et al.
Publicado: (2021)

The Gut–Vascular Barrier as a New Protagonist in Intestinal and Extraintestinal Diseases
por: Di Tommaso, Natalia, et al.
Publicado: (2023)

Molecular Mechanisms Underlying Vascular Liver Diseases: Focus on Thrombosis
por: Giuli, Lucia, et al.
Publicado: (2023)

Low ADAMTS-13/VWF ratio and altered gut–liver axis predict complications of advanced chronic liver disease: a pilot study
por: Ponziani, Francesca Romana, et al.
Publicado: (2022)

Role of Akkermansia in Human Diseases: From Causation to Therapeutic Properties
por: Pellegrino, Antonio, et al.
Publicado: (2023)

The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence
por: Cerreto, Maria, et al.
Publicado: (2023)

NAFLD or comorbidities, that is the question
por: Ponziani, Francesca Romana, et al.
Publicado: (2020)

Endotoxemia and Gastrointestinal Cancers: Insight into the Mechanisms Underlying a Dangerous Relationship
por: Manilla, Vittoria, et al.
Publicado: (2023)

Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers
por: Cerrito, Lucia, et al.
Publicado: (2019)

SIRT in 2025
por: Ponziani, Francesca Romana, et al.
Publicado: (2022)

Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation
por: Ponziani, Francesca Romana, et al.
Publicado: (2017)

Editorial: “Cancer Immunotherapy: Lights and Shadows”
por: Barrio, María Marcela, et al.
Publicado: (2015)

Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy
por: Airola, Carlo, et al.
Publicado: (2023)

Multiparametric Dynamic Ultrasound Approach for Differential Diagnosis of Primary Liver Tumors
por: Ainora, Maria Elena, et al.
Publicado: (2023)

Gut Dysbiosis and Fecal Calprotectin Predict Response to Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma
por: Ponziani, Francesca Romana, et al.
Publicado: (2022)

Immunotherapy for the treatment of hepatocellular carcinoma: finally in clinical practice
por: Celsa, Ciro, et al.
Publicado: (2023)

Subclinical atherosclerosis is linked to small intestinal bacterial overgrowth via vitamin K2-dependent mechanisms
por: Ponziani, Francesca Romana, et al.
Publicado: (2017)

Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: The Prognostic Role of Liver Stiffness Measurement
por: Cerrito, Lucia, et al.
Publicado: (2023)

Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C
por: Ponziani, Francesca Romana, et al.
Publicado: (2017)

Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation
por: Nicoletti, Alberto, et al.
Publicado: (2019)

Effect of liver transplantation on intestinal permeability and correlation with infection episodes
por: Ponziani, Francesca Romana, et al.
Publicado: (2020)

Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma
por: Kikuchi, Luciana, et al.
Publicado: (2014)

Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease
por: Inayat, Faisal, et al.
Publicado: (2016)

Improved gut microbiota features after the resolution of SARS‑CoV‑2 infection
por: De Maio, Flavio, et al.
Publicado: (2021)

Lights and Shadows
Publicado: (1897)

Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate
por: Faccia, Mariella, et al.
Publicado: (2019)

Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease
por: Sumida, Yoshio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qriv6fbh2eh9a62meojo4cipmd